In addition, the regulating or inhibiting factors of m6A modifications may act as potential strategies for cancer treatments, as observed for MA2 in glioblastoma multiforme, R-2HG/SPI1/FB23-2 in acute myeloid leukemia, and CA4 in colorectal cancer (Zhang et al., 2016; Weng et al., 2017; Su et al., 2018; Huang et al., 2019). The gene discussed is PNMA2; the disease is colorectal cancer.